CN110577897A - A method for rapidly isolating Lactobacillus reuteri from mouse intestine - Google Patents
A method for rapidly isolating Lactobacillus reuteri from mouse intestine Download PDFInfo
- Publication number
- CN110577897A CN110577897A CN201910929608.5A CN201910929608A CN110577897A CN 110577897 A CN110577897 A CN 110577897A CN 201910929608 A CN201910929608 A CN 201910929608A CN 110577897 A CN110577897 A CN 110577897A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- culture
- lactobacillus
- culture medium
- agar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 37
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 25
- 210000000936 intestine Anatomy 0.000 title description 4
- 229920001817 Agar Polymers 0.000 claims abstract description 22
- 241000186660 Lactobacillus Species 0.000 claims abstract description 22
- 239000008272 agar Substances 0.000 claims abstract description 22
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 19
- 239000001963 growth medium Substances 0.000 claims abstract description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 102000016938 Catalase Human genes 0.000 claims abstract description 7
- 108010053835 Catalase Proteins 0.000 claims abstract description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 7
- 229930006000 Sucrose Natural products 0.000 claims abstract description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 7
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims abstract description 7
- 239000005720 sucrose Substances 0.000 claims abstract description 7
- 241000699670 Mus sp. Species 0.000 claims abstract description 6
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims abstract description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims abstract description 6
- 238000012360 testing method Methods 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims abstract description 5
- 238000002474 experimental method Methods 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 5
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- 239000012137 tryptone Substances 0.000 claims abstract description 5
- 210000004556 brain Anatomy 0.000 claims abstract description 4
- 238000000746 purification Methods 0.000 claims abstract description 3
- 238000009631 Broth culture Methods 0.000 claims abstract 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract 2
- 210000001072 colon Anatomy 0.000 claims abstract 2
- 239000002609 medium Substances 0.000 claims description 29
- 241000894006 Bacteria Species 0.000 claims description 23
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 11
- 238000012136 culture method Methods 0.000 claims description 5
- 239000012154 double-distilled water Substances 0.000 claims description 5
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 210000004534 cecum Anatomy 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- 238000003794 Gram staining Methods 0.000 abstract description 5
- 238000012258 culturing Methods 0.000 abstract description 2
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 1
- 241000535428 Lactobacillus reuteri DSM 20016 Species 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000002955 isolation Methods 0.000 description 8
- 239000006872 mrs medium Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- 239000007621 bhi medium Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229930186222 escin Natural products 0.000 description 2
- 229940011399 escin Drugs 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 229940120668 salicin Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及罗伊氏乳杆菌的分离方法,特别涉及一种快速分离小鼠肠道罗伊氏乳杆菌的方法。The invention relates to a method for isolating Lactobacillus reuteri, in particular to a method for rapidly isolating Lactobacillus reuteri in mouse intestines.
背景技术Background technique
肠道微生物组是共生于肠道中庞大而复杂的生物群落,广泛参与消化吸收、免疫代谢、神经发育等功能,与健康和疾病有着密切关联。目前肠道微生物已被认为是一个独立的“器官”,然而其发挥生理、病理作用的机制尚不明确。肠道菌的高效分离培养是全面研究其生化特征、明确其生物功能和机制并推动临床转化的有力支撑和重要基础。然而,由于生长因子需求和培养条件的差异,目前对于大部分细菌仍缺乏针对性的分离培养方法,建立不同菌株的个体化培养条件仍需要大量的研究工作。Gut microbiome is a large and complex biological community that symbiotically lives in the intestine, and is widely involved in digestion and absorption, immune metabolism, neurodevelopment and other functions, and is closely related to health and disease. At present, intestinal microbes have been considered as an independent "organ", but the mechanism of their physiological and pathological effects is still unclear. The efficient isolation and culture of intestinal bacteria is a strong support and an important basis for comprehensively studying their biochemical characteristics, clarifying their biological functions and mechanisms, and promoting clinical transformation. However, due to differences in growth factor requirements and culture conditions, there is still a lack of targeted isolation and culture methods for most bacteria, and the establishment of individual culture conditions for different strains still requires a lot of research work.
罗伊氏乳杆菌(Lactobacillusreuteri)是目前已知的几乎可存在于所有脊椎动物和哺乳动物肠道内的一种乳酸杆菌。研究表明,罗伊氏乳杆菌具有调节肠道微生态、改善过敏体质、缓解免疫功能紊乱等等功能,已成为国际上公认的新型益生乳酸菌,具有很高的理论研究和生产应用价值。目前针对罗伊氏乳杆菌的分离和培养方法大多基于常规乳酸杆菌的MRS肉汤培养基。市面上针对罗伊氏乳杆菌的培养方法有用玉米粉或玉米粉等一系列农作物联合培养,步骤繁琐,不适用实验室即用即配;也有用MRS改良培养基,然而,同种水平的乳杆菌在MRS培养基中形态相似,均为白色不透明、圆或轻微不规则状,肉眼不易观察且人工筛菌程序繁杂;同时,罗伊氏乳杆菌在MRS上的生长时间相对于其他乳杆菌较延迟,生长状态颗粒小,扁平,培养时间需要48-72h,生长耗时久。因此,常规乳酸杆菌分离培养基(MRS培养基)并不能满足高效分离培养罗伊氏乳杆菌的要求,改良相关方法对于深入研究其功能和应用转化具有重要价值。Lactobacillus reuteri (Lactobacillus reuteri) is currently known as a type of lactobacillus that can exist in the intestinal tract of almost all vertebrates and mammals. Studies have shown that Lactobacillus reuteri has the functions of regulating intestinal microecology, improving allergic constitution, alleviating immune dysfunction, etc. It has become a new type of probiotic lactic acid bacteria recognized internationally, and has high theoretical research and production application value. Most of the current isolation and culture methods for Lactobacillus reuteri are based on the MRS broth medium of conventional Lactobacillus. The cultivation methods for Lactobacillus reuteri on the market use cornmeal or a series of crops such as cornflour to cultivate jointly. Bacteria in the MRS medium are similar in shape, all are white opaque, round or slightly irregular, difficult to observe with the naked eye, and the manual screening procedure is complicated; at the same time, the growth time of Lactobacillus reuteri on MRS is shorter than that of other lactobacilli. Delayed, the growth state particles are small and flat, the culture time needs 48-72h, and the growth takes a long time. Therefore, conventional Lactobacillus isolation medium (MRS medium) cannot meet the requirements for efficient isolation and cultivation of Lactobacillus reuteri, and improving related methods is of great value for in-depth research on its function and application transformation.
发明内容Contents of the invention
发明目的:本发明目的是提供可以通过高效分离且肉眼明显观察的从小鼠肠道内容物中快速分离罗伊氏乳杆菌的方法。Purpose of the invention: The purpose of the invention is to provide a method for rapidly isolating Lactobacillus reuteri from mouse intestinal contents through efficient separation and obvious visual observation.
技术方案:本发明提供一种快速分离小鼠肠道罗伊氏乳杆菌的方法,包括如下步骤:Technical solution: The present invention provides a method for rapidly isolating Lactobacillus reuteri from mouse intestines, comprising the following steps:
(1)取小鼠盲肠内容物在MRS肉汤培养基中进行罗伊氏乳杆菌的选择性初步培养,获得混合菌群,厌氧培养72h做革兰氏染色镜检和触酶试验,通过镜检结果为杆状、革兰氏染色阳性、触酶阴性的菌确证为乳酸杆菌;(1) Take the mouse cecal contents and carry out the selective primary culture of Lactobacillus reuteri in MRS broth medium to obtain mixed flora, anaerobic culture for 72 hours to do Gram staining microscopic examination and catalase test, and pass Microscopic examination results showed that rod-shaped, Gram-positive and catalase-negative bacteria were confirmed as Lactobacillus;
(2)将混合菌群接种至LAMVAB平板培养基上进行传代培养,通过颜色和形态观察分离出不同种水平的乳酸杆菌;(2) Inoculate the mixed flora on the LAMVAB plate medium for subculture, and isolate different levels of Lactobacillus through color and shape observation;
(3)挑取菌落形态为全淡绿色,圆整且相对较大的菌株接种至改良的BHI琼脂培养基上纯化培养。(3) Pick the colonies whose colonies are all light green, round and relatively large, and inoculate them on the improved BHI agar medium for purification and culture.
(4)培养18h即可做生化鉴定实验,其中仅代谢麦芽糖、棉子糖、蔗糖即确证为罗伊氏乳杆菌(Lactobacillusreuteri)。;(4) After culturing for 18 hours, the biochemical identification test can be done, and it can be confirmed as Lactobacillus reuteri only by metabolizing maltose, raffinose, and sucrose. ;
进一步地,所述步骤(3)中改良的BHI琼脂培养基配方为脑心浸液粉3.5g,胰蛋白胨2g,氯化钠1g,十二水合磷酸氢二钠1.26g,葡萄糖1g(1%),琼脂2g(2%),吐温80100μL,100mL ddH2O。Further, the formula of the improved BHI agar medium in the step (3) is 3.5g of brain heart extract powder, 2g of tryptone, 1g of sodium chloride, 1.26g of disodium hydrogen phosphate dodecahydrate, 1g of glucose (1% ), agar 2g (2%), Tween 80 100μL, 100mL ddH 2 O.
进一步地,所述MRS肉汤培养基配方为MRS粉末5.224g,100mlLddH2O。Further, the formula of the MRS broth medium is 5.224g of MRS powder and 100ml of LddH 2 O.
进一步地,所述LAMVAB平板培养基配方为LAMVAB琼脂7.25g,琼脂2g(2%),100mLdd H2O,万古霉素2mg。Further, the formulation of the LAMVAB plate medium is 7.25 g of LAMVAB agar, 2 g of agar (2%), 100 mL of dd H2O, and 2 mg of vancomycin.
进一步地,所述步骤(1)中初步培养方法为在生物安全柜中解剖健康小鼠,用无菌注射器吸取盲肠内容物,注入液体MRS培养基中,于厌氧操作箱内选择性增菌,获得混合菌群。Further, the preliminary culture method in the step (1) is to dissect a healthy mouse in a biological safety cabinet, draw the contents of the cecum with a sterile syringe, inject it into the liquid MRS medium, and selectively enrich the bacteria in the anaerobic operation box , to obtain a mixed flora.
进一步地,所述步骤(2)中传代培养分离出不同种水平的罗伊氏乳杆菌的方法为用无菌接种环将混合菌群接种到LAMVAB平板培养基上,划线培养,培养过程中不同的代谢产物质与溴甲酚绿反应,得到颜色不同、大小不同的菌群。Further, in the step (2), the method of subculturing and isolating different levels of Lactobacillus reuteri is to use a sterile inoculation loop to inoculate the mixed flora on the LAMVAB plate medium, streak culture, and during the culture process Different metabolites reacted with bromocresol green to obtain bacterial colonies with different colors and sizes.
本发明采取三步培养法,利用三种不同成分的固体或液体状态的培养基,分别进行乳酸杆菌的选择性分离和传代培养:MRS培养基具有分离乳酸杆菌的作用,从属水平缩小筛选范围;LAMVAB培养基利用细菌与其成分中的溴甲酚绿显色反应,肉眼可明显观察出菌群的生长规律,总结菌种数目。总的来说,在提高每个步骤菌群特异性的同时简化了培养组学中生化鉴定的程序,提高了细菌筛查的重复性和便利性;The present invention adopts a three-step culture method, and uses three kinds of solid or liquid culture medium with different components to carry out selective isolation and subculture of lactobacillus respectively: the MRS medium has the function of isolating lactobacillus, and the subordination level narrows the screening range; LAMVAB medium utilizes the color reaction between bacteria and bromocresol green in its components, and the growth law of the bacteria group can be clearly observed with the naked eye, and the number of bacteria species can be summarized. In general, while improving the specificity of each step, the procedure of biochemical identification in culture omics is simplified, and the repeatability and convenience of bacterial screening are improved;
有益效果:本发明的BHI改良培养基方便获得、配制简单,菌生长耗时短,适用于实验室使用。本发明的方法建立了一种罗伊氏乳杆菌的快速、简便培养条件,可在改良的BHI培养基上获得生长状态良好的单一菌落。本发明方法创造了一种耗时少、原材料简单,更适合罗伊氏乳杆菌等难培养乳酸杆菌的分离流程和生长培养。Beneficial effects: the improved BHI culture medium of the present invention is convenient to obtain, simple to prepare, takes a short time to grow bacteria, and is suitable for laboratory use. The method of the invention establishes a rapid and convenient culture condition for the Lactobacillus reuteri, and can obtain a single colony with good growth state on the improved BHI medium. The method of the invention creates a process for the separation and growth of difficult-to-culture lactobacilli such as Lactobacillus reuteri and other difficult-to-cultivate lactobacilli with less time consumption and simple raw materials.
附图说明Description of drawings
图1:乳酸杆菌的生化鉴定图,罗伊氏乳杆菌DSM20016(拉丁文名:Lactobacillusreuteri DSM20016)生化鉴定特征:在七叶苷、纤维二糖、麦芽糖、甘露醇、水杨苷、山梨醇、蔗糖和棉子糖这8种碳水化合物中,罗伊氏乳杆菌仅代谢麦芽糖、蔗糖和棉子糖,在这3种生化鉴定液中显阳性,溶液由蓝紫色在12-24h间变成黄色,图中:打“√”表示为代谢特征符合罗伊氏乳杆菌;Figure 1: Biochemical identification diagram of Lactobacillus, Lactobacillus reuteri DSM20016 (Latin name: Lactobacillus reuteri DSM20016) biochemical identification characteristics: in escin, cellobiose, maltose, mannitol, salicin, sorbitol, sucrose Among the 8 carbohydrates, Lactobacillus reuteri only metabolizes maltose, sucrose and raffinose, and was positive in these 3 biochemical identification solutions, and the solution changed from blue purple to yellow within 12-24 hours. In the figure: "√" indicates that the metabolic characteristics conform to Lactobacillus reuteri;
图2:LAMVAB空白平板(左)和LAMVAB平板接种乳酸杆菌生长72h的菌落图(右)从MRS肉汤里接种乳酸杆菌至LAMVAB琼脂培养基,72h后,培养基由淡绿色变成淡黄色;Figure 2: Lactobacillus colonies grown on LAMVAB blank plate (left) and LAMVAB plate inoculated for 72 hours (right) Lactobacillus was inoculated from MRS broth to LAMVAB agar medium. After 72 hours, the medium changed from light green to light yellow;
图3:罗伊氏乳杆菌DSM20016分别在改良BHI固体培养基(左)和MRS培养基(右)上生长18h的菌落图;Figure 3: Colony diagrams of Lactobacillus reuteri DSM20016 grown on the improved BHI solid medium (left) and MRS medium (right) for 18 hours respectively;
图4:罗伊氏乳杆菌DSM20016分别在改良BHI固体培养基(左)和MRS培养基(右)上生长24h的菌落图;Figure 4: Colony diagrams of Lactobacillus reuteri DSM20016 grown on the improved BHI solid medium (left) and MRS medium (right) for 24 hours respectively;
同一时间,同一培养条件,接种罗伊氏乳杆菌DSM20016至改良BHI和MRS平板培养基中,观察18h(见图3)及24h(见图4)的生长状态,平行比较改良BHI作为罗伊氏乳杆菌发酵培养基的优势,结果表明:罗伊氏乳杆菌DSM20016在改良BHI培养基上生长速度快,能在较短时间内获得菌落进行后续试验。菌落形态明显且分散,呈乳白色,圆形(或轻微不规则状)凸起,嗅有酸奶味。而在MRS培养基上生长缓慢,菌落颗粒小、扁平,肉眼不易观察。At the same time, under the same culture conditions, inoculate Lactobacillus reuteri DSM20016 into the improved BHI and MRS plate medium, observe the growth status of 18h (see Figure 3) and 24h (see Figure 4), and compare in parallel the improved BHI as Reuteri's The advantages of Lactobacillus fermentation medium, the results show that: Lactobacillus reuteri DSM20016 grows fast on the improved BHI medium, and can obtain colonies in a short period of time for subsequent experiments. The colonies are distinct and scattered, milky white, round (or slightly irregular) raised, and smell like yogurt. On the MRS medium, the growth is slow, and the colony particles are small and flat, which are difficult to observe with the naked eye.
具体实施方式Detailed ways
实施例1:从小鼠新鲜的肠道内容物中初步分离出乳酸杆菌属Example 1: Preliminary isolation of Lactobacillus from fresh intestinal contents of mice
提前准备无菌器材,生物安全柜中解剖正常健康小鼠,用1ml无菌注射器吸取新鲜的盲肠内容物,打入新鲜配置且预还原48h的液体MRS培养基中,于37℃厌氧操作箱内选择性增菌,进行乳酸杆菌属的初步分离。(注意:液体培养基中的菌容易被污染,用新鲜粪便发酵一次即可。镜检显示,第二次存在污染现象,出现球状阴性菌。)72h后,做革兰氏染色,显微镜下观察到基本都是杆状的革兰氏阳性菌。Prepare sterile equipment in advance, dissect normal healthy mice in a biosafety cabinet, draw fresh cecal contents with a 1ml sterile syringe, put them into freshly prepared and pre-reduced liquid MRS medium for 48 hours, and store them in an anaerobic operation box at 37°C Internal selective enrichment for the preliminary isolation of Lactobacillus. (Note: the bacteria in the liquid medium are easily contaminated, just ferment once with fresh feces. Microscopic examination shows that there is pollution for the second time, and spherical negative bacteria appear.) After 72 hours, do Gram staining and observe under the microscope to basically rod-shaped Gram-positive bacteria.
MRS肉汤培养基(100mL)配方为MRS粉末5.224g,加入100mL ddH2O。The formula of MRS broth medium (100mL) is MRS powder 5.224g, add 100mL ddH 2 O.
实施例2:从LAMVAB固体培养基分离罗伊氏乳杆菌72h后,用无菌接种环将混合菌群从增菌液接种到LAMVAB平板培养基进行分离上,可同时划线3-5个板,增加筛菌几率。菌落在培养过程发生代谢,LAMVAB培养基颜色由绿色变浅黄色(见图2左)。72h后,通过菌产生的物质与溴甲酚绿反应的显色情况不同得到一系列大小不一、显色状态不同的绿色菌群,筛选并总结菌落形态。将形态一致的菌归为一种,并编号记录1/2/3…根据实验经验结果显示,LAMVAB琼脂培养基上菌落形态为全淡绿,圆整且菌落形态相对较大的菌,后期生化鉴定结果符合罗伊氏乳杆菌的生化指标。Example 2: After isolating Lactobacillus reuteri from the LAMVAB solid medium for 72 hours, use a sterile inoculation loop to inoculate the mixed flora from the enrichment solution to the LAMVAB plate medium for separation, and 3-5 plates can be streaked at the same time , increase the chance of sieving bacteria. The colony undergoes metabolism during the culture process, and the color of the LAMVAB medium changes from green to light yellow (see Figure 2 left). After 72 hours, a series of green bacterial colonies with different sizes and different coloring states were obtained through the different coloring conditions of the reaction between the substances produced by the bacteria and bromocresol green, and the colony morphology was screened and summarized. Classify the bacteria with the same shape into one type, and record the numbers as 1/2/3...According to the experimental results, the colony shape on the LAMVAB agar medium is all light green, round and relatively large. The identification results were in line with the biochemical indicators of Lactobacillus reuteri.
LAMVAB琼脂培养基(100mL):LAMVAB琼脂7.25g,琼脂2g(2%),加入100mL ddH2O。121℃高压灭菌15分钟,冷却至50℃左右,加入过滤除菌的万古霉素2mg,左右轻微摇匀,勿引入气泡。LAMVAB agar medium (100 mL): LAMVAB agar 7.25 g, agar 2 g (2%), add 100 mL ddH2O. Autoclave at 121°C for 15 minutes, cool to about 50°C, add filter-sterilized vancomycin 2 mg, shake slightly from side to side, and do not introduce air bubbles.
菌落形态及生化鉴定结果如下表1,LAMVAB培养基中主要有以下7种形态的菌:The colony morphology and biochemical identification results are shown in Table 1. There are mainly 7 types of bacteria in the LAMVAB medium:
表1菌落形态及生化鉴定结果Table 1 Colony morphology and biochemical identification results
实施例3:利用改良BHI固体培养基快速培养罗伊氏乳杆菌Embodiment 3: Utilize the improved BHI solid medium to rapidly cultivate Lactobacillus reuteri
将生长状态一致的菌落归为一类,纯化传代至BHI改良琼脂培养基上(见图2右),并编号记录1.1/1.2/1.3/2.1/2.2...(首数字代表第几个平板,后数字代表同一个平板中有几种不同菌)。以上菌的体外培养均在厌氧(H2:10%;CO2:5%;N2:85%)恒温培养箱37℃条件下。Classify the colonies with consistent growth status into one category, purify and pass on to the BHI modified agar medium (see Figure 2, right), and record the numbers 1.1/1.2/1.3/2.1/2.2... (the first number represents the number of the plate , the last number represents several different bacteria in the same plate). The above bacteria were cultured in vitro in an anaerobic (H 2 : 10%; CO 2 : 5%; N 2 : 85%) constant temperature incubator at 37°C.
改良的脑心浸液(BHI)琼脂培养基(100mL)配方为脑心浸液粉3.5g(生产企业:美国BD公司),胰蛋白胨2g,氯化钠1g,十二水合磷酸氢二钠1.26g,葡萄糖1g(1%),琼脂2g(2%),吐温80(0.1%)100μ L,加入100mL ddH2O。121℃高压灭菌15分钟。The formula of improved brain-heart infusion (BHI) agar medium (100 mL) is 3.5 g of brain-heart infusion powder (manufacturer: American BD Company), 2 g of tryptone, 1 g of sodium chloride, and 1.26 g of disodium hydrogen phosphate dodecahydrate. g, glucose 1g (1%), agar 2g (2%), Tween 80 (0.1%) 100μL, add 100mL ddH 2 O. Autoclave at 121°C for 15 minutes.
实施例4:生化鉴定和测序为罗伊氏乳杆菌DSM20016Example 4: Biochemical identification and sequencing for Lactobacillus reuteri DSM20016
18h后,分别进行革兰氏染色、触酶试验(与15%过氧化氢反应),试验顺序依次进行,符合每一项指标后再进行下一项,否则排除该类菌株。筛选得到触酶试验为阴性、革兰氏阳性、形态为杆状的菌,进行生化鉴定,即与8种碳水化合物(七叶苷、水杨苷、麦芽糖、蔗糖、棉子糖、甘露醇、山梨醇及纤维二糖)反应得到符合罗伊氏乳杆菌生化指标的菌株(见图1)。这里需要大批量生化鉴定,可在96孔板中各取100μL生化试剂,加入无菌水重悬的菌悬液20-50μL或用接种环直接挑入菌落,厌氧条件培养18-24h后,碳水化合物结果显示仅蔗糖、麦芽糖、棉子糖反应液显阳性(紫色变黄色),故可从生化特性、代谢特性、遗传特性角度初步判定为罗伊氏乳杆菌。后续再从基因组水平提取纯化菌种的DNA,检测核酸中的蛋白等有机物的污染程度,OD260/OD280比值在1.8-2.2之间说明纯度符合标准。在q-PCR扩增的定量实验中,察看溶解曲线,确定引物和菌DNA结合的特异性,区分并验证菌株的种水平。在琼脂糖凝胶电泳的定性实验中,根据DNA分子量呈现的单条带显色检测菌种水平的完整性,即无拖尾现象。为了确定到菌的株水平,进行基因全长测序(3730测序)的菌种鉴定,根据blast结果,样品为Lactobacillus reuteri DSM 20016,complete genome,且所分离菌的核酸测序序列显示结果均为罗伊氏乳杆菌DSM20016,见表2.After 18 hours, Gram staining and catalase test (reaction with 15% hydrogen peroxide) were carried out respectively, and the test sequence was carried out in sequence, and the next one was carried out after each index was met, otherwise such strains were excluded. The catalase test was negative, Gram-positive, and rod-shaped bacteria were screened, and biochemical identification was carried out, that is, with 8 kinds of carbohydrates (escin, salicin, maltose, sucrose, raffinose, mannitol, Sorbitol and cellobiose) were reacted to obtain strains that met the biochemical indicators of Lactobacillus reuteri (see Figure 1). A large number of biochemical identifications are required here. Take 100 μL of biochemical reagents in a 96-well plate, add 20-50 μL of bacterial suspension resuspended in sterile water or directly pick colonies with an inoculation loop, and culture them under anaerobic conditions for 18-24 hours. Carbohydrate results showed that only sucrose, maltose, and raffinose were positive (purple turned yellow), so it can be preliminarily determined as Lactobacillus reuteri from the perspective of biochemical characteristics, metabolic characteristics, and genetic characteristics. Subsequently, the DNA of the purified strain is extracted from the genome level, and the pollution degree of organic matter such as protein in the nucleic acid is detected. The OD260/OD280 ratio is between 1.8-2.2, indicating that the purity meets the standard. In the quantitative experiment of q-PCR amplification, observe the melting curve, determine the specificity of primer and bacterial DNA binding, and distinguish and verify the species level of the strain. In the qualitative experiment of agarose gel electrophoresis, the integrity of the strain level is detected according to the color development of a single band presented by the DNA molecular weight, that is, there is no tailing phenomenon. In order to determine the strain level of the bacteria, full-length gene sequencing (3730 sequencing) was carried out for bacterial species identification. According to the blast results, the sample was Lactobacillus reuteri DSM 20016, complete genome, and the nucleic acid sequencing sequence of the isolated bacteria showed that the results were all Roy Lactobacillus subtilis DSM20016, see table 2.
表2罗伊氏乳杆菌DSM20016(拉丁文名:Lactobacillusreuteri DSM20016)菌落特性Table 2 Lactobacillus reuteri DSM20016 (Latin name: Lactobacillus reuteri DSM20016) colony characteristics
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910929608.5A CN110577897A (en) | 2019-09-27 | 2019-09-27 | A method for rapidly isolating Lactobacillus reuteri from mouse intestine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910929608.5A CN110577897A (en) | 2019-09-27 | 2019-09-27 | A method for rapidly isolating Lactobacillus reuteri from mouse intestine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110577897A true CN110577897A (en) | 2019-12-17 |
Family
ID=68813976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910929608.5A Pending CN110577897A (en) | 2019-09-27 | 2019-09-27 | A method for rapidly isolating Lactobacillus reuteri from mouse intestine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110577897A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1511945A (en) * | 2002-12-30 | 2004-07-14 | 中国农业大学 | Lactobacillus strain and its isolation and breeding method and application |
US20050003383A1 (en) * | 1999-06-30 | 2005-01-06 | Arkion Life Sciences Llc D/B/A Bio-Technical Resources Division | Linoleate isomerase |
WO2005021575A2 (en) * | 2003-08-29 | 2005-03-10 | Gregor Reid | Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties |
WO2005095656A1 (en) * | 2004-03-31 | 2005-10-13 | Alberto Cresci | Lactic acid bacteria strains exhibiting probiotic properties and compositions comprising the same |
CN105283191A (en) * | 2012-09-25 | 2016-01-27 | 阿曲龙Cyl有限公司 | Probiotic and prebiotic compositions |
-
2019
- 2019-09-27 CN CN201910929608.5A patent/CN110577897A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050003383A1 (en) * | 1999-06-30 | 2005-01-06 | Arkion Life Sciences Llc D/B/A Bio-Technical Resources Division | Linoleate isomerase |
CN1511945A (en) * | 2002-12-30 | 2004-07-14 | 中国农业大学 | Lactobacillus strain and its isolation and breeding method and application |
WO2005021575A2 (en) * | 2003-08-29 | 2005-03-10 | Gregor Reid | Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties |
WO2005095656A1 (en) * | 2004-03-31 | 2005-10-13 | Alberto Cresci | Lactic acid bacteria strains exhibiting probiotic properties and compositions comprising the same |
CN105283191A (en) * | 2012-09-25 | 2016-01-27 | 阿曲龙Cyl有限公司 | Probiotic and prebiotic compositions |
Non-Patent Citations (3)
Title |
---|
R. HARTEMINK等: ""LAMVAB—A new selective medium for the isolation of lactobacilli from faeces"", 《JOURNAL OF MICROBIOLOGICAL METHODS》 * |
曾杨清: "《食品微生物检验技术》", 31 January 2016, 西南交通大学出版社 * |
王斌等: ""1株肠道高黏附性乳杆菌的分离鉴定"", 《中国生物制品学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115786198B (en) | Lactobacillus paracasei and application thereof | |
CN115747111B (en) | Pediococcus pentosaceus and application thereof | |
CN108728382A (en) | One plant of tool norcholesterol and lactobacillus plantarum and its application for promoting enteron aisle short chain fatty acids generation ability | |
CN109536406B (en) | Weak post-acidification streptococcus thermophilus JMCC16, separation and purification method and application | |
CN115820498B (en) | Lactobacillus plantarum YJ2406 and application thereof | |
CN110129219B (en) | A strain of Pediococcus pentosaceus and its application | |
CN115895973B (en) | A strain of Lactobacillus paracasei and its application in the fermentation preparation of white sour soup | |
CN116463264B (en) | Lactobacillus plantarum with colon cancer cell growth inhibitory effect and its application | |
CN106434482B (en) | A strain of Lactobacillus plantarum SG5 producing γ-aminobutyric acid | |
NL2037685A (en) | Lactobacillus plantarum nxu0011 and application thereof | |
Nagyzbekkyzy et al. | Data on the diversity of lactic acid bacteria isolated from raw and fermented camel milk | |
CN106282322A (en) | A kind of Laboratory Animal Resource quality quick monitoring method | |
CN115725456A (en) | A kind of Lactobacillus salivarius and application thereof | |
Cong et al. | Isolation and identification of blueberry-derived lactic acid bacteria and their probiotic, antioxidant, and fermentation properties | |
CN114196566A (en) | Streptococcus thermophilus JMCC0033 and application thereof | |
CN109112067B (en) | A method for screening microorganisms in tobacco fermentation process assisted by metagenomic sequencing | |
CN110577897A (en) | A method for rapidly isolating Lactobacillus reuteri from mouse intestine | |
Patil et al. | Isolation and characterisation of Lactobacillus species from sheep milk | |
TWI804307B (en) | Probiotic composition for improving memory and learning ability and use thereof | |
KR101748560B1 (en) | Pediococcus acidilactici lrcc5307 strain having ability of choloesterol assimilation and method for manufacturing cultured butter using the same | |
CN1552845A (en) | Lactobacillus casei Bd-II strain and its application in reducing blood lipid | |
CN113957023B (en) | Weak post-acidification fusion Weissella and its application | |
Kim et al. | Screening of antioxidative activity of Bifidobacterium species isolated from Korean infant feces and their identification | |
CN113604385A (en) | Lactobacillus delbrueckii with butter degrading capability and application thereof | |
CN112553118A (en) | Method for enriching beneficial bacteria by using prebiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191217 |